A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment

BACKGROUND: About 50% of patients with colorectal cancer are destined to develop hepatic metastases. Radical resection is the most effective treatment for patients with colorectal liver metastases offering five year survival rates between 36-60%. Unfortunately only 20% of patients are resectable at...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Snoeren, Nikol, Voest, Emile E, Bergman, Andre M, Dalesio, Otilia, Verheul, Henk M, Tollenaar, Rob AEM, van der Sijp, Joost RM, Schouten, Sander B, Rinkes, Inne HM Borel, van Hillegersberg, R
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2010
Sujets:
Study Protocol
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2958953/
https://ncbi.nlm.nih.gov/pubmed/20937118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-10-545
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires